A broad overview covering semaglutide, liraglutide and tirzepatide, with the full report posted on Indica's website.
Recap by typeshit. Post by @theindicanews on Instagram.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
The obesity doctor responds to upset replies on an earlier post, holding that adiposity and cardiorespiratory fitness are correlated yet separate measures.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Loading…